Business Wire

L&T Technology Services inaugurates Engineering R&D Centre in Poland to provide Embedded and Digital Solutions to Clients

Share

L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leading pure-play engineering services company, today inaugurated its Engineering, Research and Development (ER&D) centre in Krakow, Poland, which will cater to global customers, leveraging cutting edge technologies in the Automotive, Mobility and Hi-Tech domains.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005835/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Seen in the picture (from right to left): Jagyan Mishra, Delivery Head (Europe) at LTTS, Abhishek Sinha, Chief Operating Officer and Member of the Board at LTTS, Mr. Jerzy Muzyk, Deputy Mayor of the City of Krakow, Her Excellency Nagma Mohamed Mallick, Ambassador of India to the Republic of Poland, Mr. Lukasz Słoniowski, President of the Board at Investor Support Krakow and Rajkumar Ravindranathan, Chief Business Officer at LTTS, during the inauguration of the ER&D centre. (Photo: Business Wire)

The state-of-the-art centre will mark its expansion into Eastern Europe, contributing to the growth of regional economy, delivering cutting-edge technology, expanding workforce, and support major projects through its innovative engineering processes. The ER&D centre will cater to several major customers in Europe and North America, including a U.S. based automotive Tier 1 company.

In the new Engineering R&D Centre, LTTS will work on both software and hardware development of product lines. This centre is part of LTTS’ global delivery model and is a logical extension of LTTS’ Munich, Gothenburg and Jerusalem engineering centres, allowing the new centre to bring in specialized competencies along with local talent.

The ER&D centre was officially inaugurated by the Deputy Mayor of the City of Krakow, Mr. Jerzy Muzyk and Ambassador of India to the Republic of Poland, Her Excellency Nagma Mohamed Mallick, in the presence of Mr. Abhishek Sinha, Chief Operating Officer and Member of the Board, L&T Technology Services.

Known for imparting first-class technical education, academic ecosystem and infrastructure, Poland provides a pool of talented engineers who are setting a benchmark in cutting-edge technology. LTTS plans to hire up to 300 engineers in the next three years for the centre. LTTS will also utilize its in-house Global Engineering Academy (GEA) to enable employees to reskill and upskill their domain knowledge and align it to customer requirements, while exploring collaboration opportunities with AGH University Krakow, Krakow University of Technology and UK-based Coventry University to expand the engineering talent pool in Poland.

Mr. Abhishek Sinha, Chief Operating Officer and Member of the Board, L&T Technology Services, said, “By establishing this important centre in Poland, we aim to make our customers in Europe and North America benefit from LTTS’ long-standing expertise in new age engineering and embedded technologies. We also seek to tap into the local engineering talent pool for many of our mission critical global programs, and will work

with the local administration and the academia to further develop the local ecosystem. We would also like to express our gratitude for all the support we have received from government institutions and local authorities”.

Mr. Jerzy Muzyk, Deputy Mayor of the City of Krakow, commented on the inauguration, “We welcome the investments from an Engineering Services leader like LTTS. With LTTS set to contribute in important aspects like technology advancements, R&D and skill building for young engineers, I am optimistic that the local population will benefit greatly from this ER&D Hub”.

About L&T Technology Services Ltd

L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 20,800 employees spread across 17 global design centres, 28 global sales offices and 89 innovation labs as of March 31, 2022. For more information, please visit https://www.ltts.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aniruddha Basu
L&T Technology Services Limited
E: Aniruddha.Basu@LTTS.com
T: +91-80-67675707

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)24.6.2022 19:54:00 EEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 17:59:00 EEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 17:41:00 EEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 17:14:00 EEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® ▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 16:38:00 EEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom